Oropharyngeal Cancer

Docking Studies on Anticancer Drugs for Breast Cancer Using Hex

... –Breast cancer, Chemsketch, Docking, Hex, Rasmol I. INTRODUCTION Breast cancer is a cancer that starts in the cells of the breast in women and men. Worldwide, breast cancer is the second most common type of cancer after lung cancer (10.4% of all cancer incidence, both sexes counted) and the fifth most common cause of cancer death. In 2005, breast cancer ... - 20, 2009, Hong Kong Docking Studies on Anticancer Drugs for Breast Cancer Using Hex Alex Mathew J, Nixon Raj N Abstract? ?Cancer can be described as the uncontrolled growth of abnormal cells. Breast cancer is the second most common type of cancer after lung cancer. Normal breast cells and most breast cancer cells have receptors that attach to circulating ... Kong REFERENCES [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] World Health Organization Interantional Agency for research on cancer (June 2003). “World Cancer Report”. World Health Organization t, (Feb 2006). “Fact Sheet, No 297: Cancer? ??. American Cancer Society (2007).” Cancer Facts and Figures”[PDF] “Computational Biology and Drug Discovery: From single - network Drugs”,
 0  10  4

Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone.

... varies in cervical cancer cells depending on the p53 status. Cancer Biol Ther 3: 1177– 1183. 18. Koivusalo R, Krausz E, Ruotsalainen P, Helenius H, Hietanen S (2002) Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Cancer Res 62: ... using the RNeasy kit (Qiagen, Hilden, Germany). Materials and Methods Cell lines and cytotoxicity assays The human cervical cancer cell lines SiHa (HPV 16+), CaSki (HPV16+), and HeLa (HPV 18+), breast cancer cell line MCF7, and vulvar cancer cell line A431 were obtained from the American Type Culture Collection (Manassas, VA, USA). The primary human fibroblasts ... wanted to test were derived from HPV-positive cervical cancer. However, the effect appears to not have been restricted to these cells. The drugs were tested with two cancer cell lines of different origin: The vulvar carcinoma cell line A431 has a missense mutation in the p53 gene, and the MCF7 breast cancer cell line has a wild-type p53. The survival was
 0  3  12

Identification and characterization of CDH1 germline variants in sporadic gastric cancer patients and in individuals at risk of gastric cancer.

... Translational Research, Centro di Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Pordenone, Italy, 2 Pathology Unit, Centro di Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Pordenone, Italy, 3 Gastroenterology Unit, Centro di Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Pordenone, Italy, 4 CEB-Centre of Excellence ... Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Pordenone, Italy, 6 Scientific Director, Centro di Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Pordenone, Italy Abstract Objective: To screen and characterize germline variants for E-cadherin (CDH1) in non-hereditary gastric cancer (GC) patients and in subjects at ... Identification and Characterization of CDH1 Germline Variants in Sporadic Gastric Cancer Patients and in Individuals at Risk of Gastric Cancer Marica Garziera1, Vincenzo Canzonieri2, Renato Cannizzaro3, Silvano Geremia4, Laura Caggiari1, Mariangela De Zorzi1, Stefania Maiero3, Enrico
 0  2  12

Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis.

... one gallbladder adenocarcinoma). Other cancer types were also investigated, including seven studies on breast cancer, six on renal cell carcinoma, four on non-small cell lung cancer (NSCLC), three on prostate cancer, three on oral tongue squamous carcinoma, and the remaining 14 studies on 11 different types of cancer. Treatment information was not available ... cell carcinoma, breast cancer gastric cancer, and NSCLC were investigated in detail. For each disease, high EZH2 PLOS ONE | DOI:10.1371/journal.pone.0125480 May 14, 2015 9 / 17 EZH2 in Cancer Prognosis Table 3. Results of the meta-analysis of the association between nuclear EZH2 expression and MFS, PFS, CSS and DSS of multiple cancers. Meta-analysis No. ... terms of cancer prognosis. In our study, we also observed prognostic significance of EZH2 in multiple cancers. Thus, we speculate that there might be an association between EZH2 and some clinicopathological features of cancer. This hypothesis was confirmed in certain situations (mentioned above) without significant heterogeneity. However, in several cancer
 0  4  17

Developing the Evidence Base to Inform Best Practice: A Scoping Study of Breast and Cervical Cancer Reviews in Low- and Middle-Income Countries.

... cancer control strategies in LMICs. In this scoping study, roughly twice as many reviews were identified relating to cervical cancer compared with breast cancer in LMICs. While cervical cancer predominates in morbidity and mortality in some areas of the world (e.g. Sub-Saharan Africa), overall breast cancer is more prevalent in LMICs than cervical cancer ... africans a year dying from cancer by 2030: what can cancer research and control offer to the continent? International Journal of Cancer. 2012; 130(2):245–50. 5. Lodge M. Ignorance Is Not Strength: The Need For A Global Evidence Base For Cancer Control In Developing Countries. Cancer Control. 2013:153. 6. Wild CP. The role of cancer research in noncommunicable ... cervical cancer and 34 reviews of breast cancer in LMIC settings that met our eligibility criteria (Fig 1). Cervical and breast cancer reviews differed substantially (Table 2). The cervical cancer literature reflected a substantially larger volume and distribution of both systematic [14, 23–40] and non-systematic reviews [12, 41–80], while the breast cancer
 0  2  17

3D radiation therapy or intensity-modulated radiotherapy for recurrent and metastatic cervical cancer: the Shanghai Cancer Hospital experience.

... 3D Radiation Therapy or Intensity-Modulated Radiotherapy for Recurrent and Metastatic Cervical Cancer: The Shanghai Cancer Hospital Experience Su-Ping Liu, Xiao Huang*, Gui-Hao Ke, Xiao-Wei Huang Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, China Abstract We evaluate the outcomes of irradiation by using three-dimensional ... platinum-based chemotherapy. In 1999, the US National Cancer Institute recommended using cisplatin-based chemotherapy during radiation for cervical cancer based on several cooperative clinical trials that demonstrated the benefit of the concurrent use of chemotherapy and radiation to treat locally advanced and high-risk cervical cancer [20,21,22,23,24]. Nedaplatin, ... grade 2 or less [18]. Due to large size of the recurrent cancer (median 4.5 cm) and peripheral location (n = 12), SBRT (median 3 fractions of 5 Gy to 65%) was used for local dose escalation after 50 Gy conventionally fractionated radiotherapy within all 19 patients (cervical cancer n = 12, endometrial cancer n = 7) in Guckenberger et al.’s report. 3-year
 0  4  8

Inhibition of mesothelin as a novel strategy for targeting cancer cells.

... SS1P. Clin Cancer Res 15: 5274–5279. Chang K, Pastan I, Willingham MC (1992) Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50: 373–381. Muminova ZE, Strong TV, Shaw DR (2004) Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. BMC Cancer 4: ... ovarian and pancreatic cancer cell lines and compare such effects with our data about mesothelioma cells. The levels of expression of MSLN in a panel of pancreatic and ovarian cancer cells were tested using western blotting as shown in figure 2A. Miapaca2, BxpC3 and Panc1 (pancreatic cancer cell lines) and Skov3 and Ovcar3 (ovarian cancer cell lines) showed ... of 4 April 2012 | Volume 7 | Issue 4 | e33214 Targeting Mesothelin for Cancer Therapy Figure 2. Mesothelin silencing reduces proliferation rate of pancreatic and ovarian cancer cells. (A)Mesothelin protein was detected in pancreatic cancer cell lines, Panc1, Miapaca2 and Bxpc3 and ovarian cancer cells Skov3 and Ovcar3. NIH3T3 and Huvec cells which are void
 0  2  11

A prospective highlight on exosomal nanoshuttles and cancer immunotherapy and vaccination

... in the Pathogenesis of Melanoma Head and Neck Cancer; Oral Mucositis Dietary supplement: grape extract James Graham Brown Cancer Center Oropharyngeal Cancer Exosome protein signature outcome measure Dietary supplement: curcumin conjugated with plant exosomes Tumor exosomes from urine and serum New Mexico Cancer Care Alliance Metastatic Melanoma Blood ... malignancies Trial ID: Description Cancer type Intervention/Experiment Sponsor NCT01779583: Circulating Exosomes As Potential Prognostic And Predictive Biomarkers In Advanced Gastric Cancer Patients ("EXO-PPP Study") NCT02393703: Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer Gastric Cancer Molecular profile ... Approaches towards Cancer Gene Therapy: Hurdles and Hopes. Bioimpacts 2012; 2: 127-43. doi:10.5681/bi.2012.025 Omidi Y. Smart multifunctional theranostics: simultaneous diagnosis and therapy of cancer. Bioimpacts 2011; 1: 145-7. doi:10.5681/bi.2011.019 Omidi Y. CNT Nanobombs for Specific Eradication of Cancer Cells: A New Concept in Cancer Theranostics.
 0  4  6

Methylation of the claudin 1 promoter is associated with loss of expression in estrogen receptor positive breast cancer.

... silencing of claudin 1 has an epigenetic etiology in breast cancer we compared gene expression and methylation data from 217 breast cancer samples and 40 matched normal samples available through the Cancer Genome Atlas (TCGA). Moreover, we analyzed claudin 1 expression and methylation in 26 breast cancer cell lines. We found that methylation of the claudin ... carcinoma [19] and claudin 6 and 7 in breast cancer [20,21], and methylation of the claudin 1 promoter has been reported in the colon cancer cell line HCT116 [22], which does not express claudin 1. Moreover, elevated methylation and low expression of claudin 1 were observed in breast cancer samples from The Cancer Genome Atlas (TCGA) [23]. To investigate ... methylation in human cancer cells. Genomics 98: 280-287. doi:10.1016/j.ygeno.2011.07.003. PubMed: 21821115. 23. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70 24. Ignatoski KM, Ethier SP (1999) Constitutive activation of pp125fak in newly isolated human breast cancer cell lines. Breast Cancer Res
 0  4  8

Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response.

... macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 128: 703–711. 34. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, et al. (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66: 11238– 11246. 35. Bolat F, Kayaselcuk F, Nursal TZ, Yagmurdur ... hazard rates of death from breast cancer. Breast Cancer Res Treat 100: 121–126. 3. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, et al. (2005) Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11: 951s–958s. 4. Baum ... residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 18: 1052–1059. 14. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, et al. (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103:
 0  2  9


... breast cancer: An update. Ontario Clinical Oncology Group. J Natl Cancer Inst. 1996; 88:1659–1664; 9. Liljegren G, Holmberg L, Adami HO, Westman G, Graffman S, Bergh J. – Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial. Uppsala-Orebro Breast Cancer Study Group. J Natl Cancer ... the standard radical surgery of breast cancer (11,12). Notable progress made in recent decades in volume 1 • issue 4 October / December 2011 • pp 335-340 THERAPEUTIC OPTIONS FOR BREAST CANCER the field of adjuvant and neoadjuvant therapy, and the appearance of the “systemic” pattern in the behavior of breast cancer have led to a gradual restriction ... chemotherapy for the treatment of early-stage, node-positive breast cancer: Sequencing, timing, and outcome. J Clin Oncol. 1991; 9:1662–1667; 3. Buchholz TA, Hunt KK, Amoss CM, Tucker SL, Strom EA, McNeese MD, et al. – Sequencing of chemotherapy and radiation in lymph nodenegative breast cancer. Cancer J Sci Am. 1999; 5:159–164; 4. De Cuyper L, Van Hee R,
 0  3  6

Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing.

... lung cancer is cigarette smoking, and increased exposure is directly correlated with an increased risk of developing lung cancer [4]. 85–90% of lung cancer deaths are associated with smoking, and current smokers are 15 times more likely to die from lung cancer than never-smokers [5]. There are two major forms of lung cancer: non-small-cell lung cancer (NSCLC) ... sample set (Table 5). Mutation analysis of human lung cancer tumors with Ion Ampliseq Cancer Panel A total of 76 Lung cancer samples (Table 1) was analyzed using Ion Torrent Ampliseq Cancer Panel to identify mutations in 737 loci of 45 oncogenes and tumor suppressor genes in human lung cancers. These Lung cancer samples were all from Chinese patients ranging ... all new cancers [1]. Additionally, roughly 1.38 million deaths (18.2% of total cancer deaths) were reported around the world [2]. In China, lung cancer has the highest incidence of all new cancer cases in both men and women (21.7% in 2008) with more than a 24.9% mortality rate [2]. Women in China reported only a slightly higher incidence of lung cancer
 0  3  16

Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoprotein.

... pathways also play important roles in cancer cell apoptosis in responses to EVO [21-23]. The objective of the present study was to determine the effects of EVO on DOXresistant breast cancer cells when treated alone and in combination with DOX. We hypothesized that EVO would enhance DOX sensitivity in DOX-resistant breast cancer cells by synchronously inhibiting ... clinical outcomes in resistant cancers [33]. Many attempts have been made to inhibit membrane transporters, however, most of these drug transporter inhibitors 4 May 2014 | Volume 9 | Issue 5 | e97512 Evodiamine Synergizes with Doxorubicin against Resistant Cancer Cells Figure 2. EVO induces apoptosis in MCF-7 and MCF-7/ADR cancer cells. (A) Hoechst ... the Ras/ MEK/ERK pathway may prevent drug resistance and the reemergence of cancer initiating cells. Many plant-derived compounds are known to enhance the chemotherapeutic effects of anticancer agents by modulating the main ABC (ATP-binding cassette) transporters responsible for cancer drug resistance, including P-gp, MRPs and BCRP, as well PLOS ONE |
 0  3  10

MRI Background Parenchymal Enhancement Is Not Associated with Breast Cancer.

... factor for breast cancer independently of overall patient breast cancer risk. Yet, BPE, first and foremost, is a sensitive measure of tissue activity, one known to be driven by hormones and thus to closely correlate with age. While, high density in mammography is an established breast cancer risk factor, no study has yet linked FGT to breast cancer risk. ... breast cancer risk in non-high risk women. In instances wherein tissue activity is a contributing risk factor, BPE will correlate with breast cancer. It is important to note that women with normal breast tissue (i.e. no familial history of breast cancer, no known mutations, no previous chest irradiation) are not more susceptible to developing breast cancer ... mammographic density and benign breast disease on breast cancer risk (United States). Cancer Causes Control CCC. 2001; 12: 103–110. PMID: 11246838 3. Vachon CM, van Gils CH, Sellers TA, Ghosh K, Pruthi S, Brandt KR, et al. Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res BCR. 2007; 9: 217. doi: 10.1186/bcr1829 PMID:
 0  3  12

The incidence of thyroid cancer at thyroidectomy materials in Malatya

... cancer 88 (53.6%) cases papillary carcinoma, 10 (6%) cases follicular carcinoma, 1 (0.6%) case medullary carcinoma, 3 (1.8%) cases were anaplastic carcinoma. Conclusion: Thyroid cancer incidence is 19.7% at thyroidectomy materials in the city of Malatya and most cancers is seen as a type of thyroid papillary carcinoma. Key words: Goitre, thyroid cancer, ... kanseri, papiller karsinom ABSTRACT Objective: Thyroid cancers are the most common malignancy of the endocrine organs. It accounts for 1% of all cancer. Environmental, genetic and hormonal factors play an important role in its etiology. The aim of this study is to investigate the incidence of thyroid cancer and types at thyroidectomy materials in the city ... 1999;5:13-16. 4. Salab GB. A etiology of thyroid cancer: an epidemiological overview. Thyroidol 1994;6:9-11. 5. Özgüven BY, Yener Ş, Başak T, ve ark. Tiroid operasyon materyali histopatolojik tanılarının retrospektif olarak değerlendirilmesi. ŞEH Tıp Bülteni 2008;42:5-9. 6. Robbins J, Merino MJ, Boice JD, et al. Thyroid cancer: a lethal endocrine neoplasm. Ann
 0  5  4

Genetic variation in selenoprotein genes, lifestyle, and risk of colon and rectal cancer.

... for colon and rectal cancer, the same genes appeared to be important. However, SelN rs4659382 was associated with significant reduced risk of both colon cancer (OR 0.76) and rectal cancer (OR 0.58). Additionally, multiple SNPs in SelN were associated with rectal cancer, as were multiple SNPs in TXNRD2 for both colon and rectal cancer, although associations ... and metastasis of colon cancer cells. Cancer Prev Res (Phila) 3: 630–639. 21. Slattery ML, Potter J, Caan B, Edwards S, Coates A, et al. (1997) Energy balance and colon cancer? ??beyond physical activity. Cancer Res 57: 75–80. 22. Slattery ML, Edwards S, Curtin K, Ma K, Edwards R, et al. (2003) Physical activity and colorectal cancer. Am J Epidemiol ... genes. TXNRD1, TXNRD2, TXNRD3, and SelN1 interacted with BMI to alter risk of colon cancer and TXNRD1 interacted with BMI to statistically alter risk associated with rectal cancer (Table 5). The adjusted risk for SelN1 and colon cancer and both TXNRD1 SNPs and rectal cancer remained statistically significant after adjustment PLoS ONE | www.plosone.org 4
 0  3  11

CXCL12 chemokine expression suppresses human pancreatic cancer growth and metastasis.

... in normal and cancerous pancreatic ductal epithelium, established cell lines, and patient-derived primary cancer cells. Relative to healthy exocrine ducts, CXCL12 expression was pathologically repressed in pancreatic cancer tissue specimens and patient-derived cell lines. To test the functional consequences of CXCL12 silencing, pancreatic cancer cell ... malignancy, the mechanisms behind pancreatic cancer dissemination and metastasis are poorly understood. Correlative pathological and cell culture analyses suggest the chemokine receptor CXCR4 plays a biological role in pancreatic cancer progression. In vivo roles for the CXCR4 ligand CXCL12 in pancreatic cancer malignancy were investigated. CXCR4 and ... CXCR4 and CCR7, in cancer progression and metastasis [9,17–22]. CXCR4 expression has been linked with the malignancy of over 20different cancers [17,23]. We have previously demonstrated that CXCL12 is expressed in normal epithelial cells in intestine and mammary glands, but is epigenetically silenced in human breast and colorectal cancer [24,25].This
 0  3  13

pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.

... ANP32A) is low in poorly differentiated pancreatic cancers and is linked to the levels of HuR (ELAV1), a predictive marker for gemcitabine response. In pancreatic cancer cells, exogenous overexpression of pp32 inhibited cell growth, supporting its long-recognized role as a tumor suppressor in pancreatic cancer. In chemotherapeutic sensitivity screening ... locally advanced/metastatic pancreatic cancer and prognostic factors. Scand J Gastroenterol 40: 1486–1492. 6. Winter JM, Maitra A, Yeo CJ (2006) Genetics and pathology of pancreatic cancer. HPB (Oxford) 8: 324–336. 7. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic ... Novel nuclear phosphoprotein pp32 is highly expressed in intermediate- and highgrade prostate cancer. Prostate 34: 231–237. 11. Kadkol SS, El Naga GA, Brody JR, Bai J, Gusev Y, et al. (2001) Expression of pp32 gene family members in breast cancer. Breast Cancer Res Treat 68: 65–73. 12. Brody JR, Kadkol SS, Mahmoud MA, Rebel JM, Pasternack GR (1999)
 0  2  11


... with unresectable NSCLC. Key words: Prognostic factors, Thrombocytosis, Non small cell lung cancer, Survival INTRODUCTION Lung cancer remains the most common cause of cancer death worldwide for both men and women. NSCLC constitutes about 75%- 85% of all lung cancer cases [1]. Despite recent improvements of diagnostic technologies, approximately 50% ...
 0  7  5

Avaliação do perfil da resposta imune Th1, TH2 e Th17 em mulheres com cancer epitelial dos ovários

 0  2  98

TCTP is an androgen-regulated gene implicated in prostate cancer.

 0  2  11

Imunonutrição e o tratamento do câncer = Immunonutrition and the cancer treatment

 0  6  6

Tamizaje del cancer de cuello de utero: presentación del número monográfico

... Cervical Cancer. En: Miller AB, ed. Adva&s in cancer screening. New York: Kluwer Academic Publishers; 1996. [Cancer 8. Eckert LO, Kautsky LA, Kiviat NB, Krone MR, Stevens CE, Eschenbaj DA. The infkammatory Papanicolaou smear: what does it mean? Obstet Gynecol1995;86:360-366. 9. Clarke, EA, Anderson TW. Does screening by “pap” smear help prevent cervical cancer? ... pap test for cervical cancer ] Clin Epidemial 1989;42:1003-1011. 11. Hakama M, Miller AB, Day NE, eds. Screeningfor cancer of the uterine cervix. Lyon: Intemational Agency for Research on Cancer, World Health Organization; 1986. 12. Aristizabal N, Cuello C, Correa P, Collazos T, Haenzel W. The impact of vaginal cytology on cervical cancer risks in Cali, ... áreas administrativa y clínica. REFERFNCJAS 1. Parkin DM, Pisani E Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Inf I Cancer 1993;54:594-606. 2. World Health Organization, Intemational Agency for Research on Cancer. Cuncer incidence in fine continents, Volume VI. Lyon: OMS; 1992. [Scientific Publication 1201. 3. Miller AB. Programas
 0  6  5

Screening for cervical cancer in Brazil

... common primary 1 3 4 5 5 4 3 2 31 cancers in men and Cervix uteri Breast Colon and rectum Stomach Corpus uteri Mouth* Hematopoietic system - I 0 I 5 I 10 I 15 I 20 Percentage of all cancers 0 1976-1980 f&Z! 1981-1985 ‘Did not rank among the 10 most common cancers in 1986-1990. 392 BuILdin of PAHO 30(4), 1996 I1986-1990 I 25 I Table 2. Mortality from cervical cancer ... adenocarcinoma, 2%. Of all cancers occurring in either men or women, cervical cancer has ranked either first or second among the 10 most common primary cancers in Brazil since 1976, as shown in Figure 1. In Porto Alegre, a city located in the state of Rio Grande do Sul, the incidence of cervical cancer was 23.7 per 100 000 women in 1979 and 1982 and 23.8 per 100 ... for Research on Cancer. Cancer incidence in five continents, volume IV Lyon: WHO; 1982. (Scientific publication 42). 3. Organization Panamericana de la Salud. Manual de normas y procedimientos para el control de1 crincer de2 cuello uterino. Wash- ington, DC: OPS; 1990. (PALTEX series, number 6). 4. World Health Organization. National cancer control
 0  7  4

Adelantos recientes en el tratamiento del cancer

... prefieren Ia vida a la laringe. * Lens, M.: Cancer of the Larynx, J. A. M. A. 134: 117 (mayo 10) 1947. * Cutler, M., en el Informe del Chicago Tumor Institute, abril 1, 1938 a marzo 31,1945. 4 Cutler, M.: Cancer of Larynx: Five-Year Results of Concentration Radiotherapy, Arch. Otolaryng. 43: 399 (abril) 1946. 6 Martin, H.: Cancer of the Larynx, in Nelson% Loose ... in Cases of Skeletal Metastases from Mammary Cancer, J. A. M. A. 118: 339 (eno. 31) 1942. r*Haddow, A.: Watkinson, J. M., y Paterson, E.: Influente of Synthetic Oestrogens upon Advanced Malignant Disease, Brit. M. J. 2: 393,1944. 11Nathanson, 1. T.: The Effects of Stilbestrol on Advanced Cancer of the Breas& Cancer Research 6: 484,1946. 208 OFICINA ... observaciones de Hamilton16 y de Frantz16 respecto a que 12Halberstaedter, L., y Hochman, A.: The Artificial of Menopause and Cancer of the Brea&, J. A.M. 8.131: 810 (julio 6) 1946. l3 Brunschwig, A.: Radical Surgery in Advanced Abdominal Cancer, Chicago, University of Chicago Press, 1947. 14Oppenheimer, E.: Carcinoma of the Rectum in Connecticut, New England
 0  3  7

Documento similar